Aurobindo Pharma receives US FDA approval for Didanosine (Chewable) Tablets

Aurobindo Pharma Ltd has announced that the US FDA has granted tentative approval for Didanosine Tablets (Chewable)of strengths 100mg, 150mg & 200mg. This is the first generic version approval of Didanosine chewable in the world given by US FDA.

The aforesaid product will now be available for consideration for purchase under the PEPFAR. The Company manufactures both API and formulation for this generic. With this approval, the ARV product portfolio of the Company has increased to 17.

Didanosine is a NRTI class of drugs, and a key component of the ARV regimens in various parts of the world. This molecule enjoys approximately $100mio. of market share.

Didanosine helps prevent AIDS virus from reproducing. It is used in combination with other antiretroviral agents for the treatment of HIV-1 infection. Didanosine is the version of VIDEX an anti-HIV medication manufactured by Bristol Myers Squibb.

Source : Equity Bulls

Keywords